ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2059

Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry

Chiharu Hidekawa1, Ryusuke Yoshimi2, Yusuke Saigusa3, Jun Tamura3, Nobuyuki Yajima4, Naoki Suzuki5, Noriko Kojitani2, Yuji Yoshioka5, Natsuki Sakurai5, Yumiko Sugiyama5, Yosuke Kunishita6, Daiga Kishimoto7, Kana Higashitani5, Yuichiro Sato5, Takaaki Komiya5, Hideto Nagai2, Naoki Hamada5, Ayaka Maeda5, Naomi Tsuchida5, Lisa Hirahara2, Yutaro Soejima5, Kaoru Takase-Minegishi2, Yohei Kirino5, Ken-ei Sada8, Yoshia Miyawaki9, Kunihiro Ichinose10, Shigeru Ohno11, Hiroshi Kajiyama12, Shuzo Sato13, Yasuhiro Shimojima14, Michio Fujiwara15 and Hideaki Nakajima5, 1Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama City, Kanagawa Prefecture, Japan, 2Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan, 4Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 5Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, 6Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Kanagawa, Japan, 7Center for Rheumatic Diseases, Yokohama City University Medical Center, Kanazawa-ku Yokohamashi, Japan, 8Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Okayama, Japan, 9Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Yokohama, Japan, 10Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Yokohama, Japan, 11Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan, 12Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, 13Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Japan, 14Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 15Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Japan

Meeting: ACR Convergence 2022

Keywords: Infection, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Infections are significant causes of mortality in patients with systemic lupus erythematosus (SLE), and their prevention is essential. Although some previous reports have shown the efficacy of hydroxychloroquine (HCQ) in preventing infection, there is no such evidence in the Japanese population. Here we investigated the effect of HCQ on reducing infections in SLE patients in Japan using data from the Lupus Registry of Nationwide Institutions (LUNA) registry.

Methods: Patients older than 20 years and who met the 1997 ACR revised classification criteria were enrolled in the LUNA registry. We defined “severe infections” as infections that required inpatient treatment, and collected data on the type of infection, treatment, disease activity, and clinical and serological variables. To analyze the protective effect of the HCQ on infections using a generalized estimating equation (GEE) logistic regression model as primary endpoint, we converted all follow-up periods to person-years at each observation point. We defined the HCQ group as the period when the patient was taking HCQ both points before and after each annual observation period and the non-HCQ group as when the patient was not taking HCQ at both points. To analyze the survival time by log-rank test and perform a multivariate analysis of the association between the HCQ and the time until the first severe infection within the observation period, we defined the HCQ group as the patients who took HCQ for at least two observation points, and the non-HCQ group as those who did not take HCQ during the follow-up period. We used multiple imputation for missing data.

Results: A total of 925 patients were included in the study (median age 45 (IQR 35-57) years; female 88.1 %; the observation period 1-5 years). At enrollment, 267 patients were prescribed HCQ, while 656 were not. The median dose of glucocorticoid was 5.5 (IQR 4.0-9.0) mg/day and systemic lupus erythematosus disease activity index (SLEDAI) was 4 (IQR 2-8). A total of 110 severe infections were reported, with pulmonary infections the most common (29.1 %), followed by urinary tract infections (27.3 %) and skin and soft tissue infections (15.5 %). To examine the effect of HCQ and other factors on severe infections, we extracted 1,990 person-years. GEE analysis showed that severe infection was positively associated with the glucocorticoid dose (odds ratio [OR] 1.96 [95% confidence interval 1.38-2.81], p = 2.0×10-4), immunosuppressive drugs (OR 1.56 [1.03-2.38], p = 0.038), and the age at baseline (OR 1.04 [1,03-1.06], p = 1.5×10-7). HCQ tended to reduce the incidence of severe infections, although the difference was not statistically significant (OR 0.59 [0,33-1.06], p = 0.077). Survival time analysis showed that the HCQ group (n = 296) had a lower incidence of severe infection than the non-HCQ group (n = 436) (p = 3.1×10-4). Using a cox proportional hazards model, we found that age at baseline (hazard ratio [HR] 1.033 [1.014-1.052], p = 6.0×10-4) and HCQ (HR 0.32 [0.142-0.723], p = 6.0×10-3) were significantly associated with incidence rate.

Conclusion: This study demonstrated that HCQ could reduce the incidence of infection, which may improve the clinical course of SLE patients.

Supporting image 1

Figure Probability of first severe infection during follow up period. The patients were divided into two groups, HCQ and non-HCQ group. We conducted a survival time analysis of first severe infection during follow up period. The results showed that the HCQ group had a significantly lower incidence of infection.


Disclosures: C. Hidekawa, None; R. Yoshimi, None; Y. Saigusa, None; J. Tamura, None; N. Yajima, None; N. Suzuki, None; N. Kojitani, None; Y. Yoshioka, None; N. Sakurai, None; Y. Sugiyama, None; Y. Kunishita, None; D. Kishimoto, None; K. Higashitani, None; Y. Sato, None; T. Komiya, None; H. Nagai, None; N. Hamada, None; A. Maeda, None; N. Tsuchida, None; L. Hirahara, None; Y. Soejima, None; K. Takase-Minegishi, None; Y. Kirino, None; K. Sada, None; Y. Miyawaki, None; K. Ichinose, None; S. Ohno, None; H. Kajiyama, None; S. Sato, None; Y. Shimojima, None; M. Fujiwara, None; H. Nakajima, None.

To cite this abstract in AMA style:

Hidekawa C, Yoshimi R, Saigusa Y, Tamura J, Yajima N, Suzuki N, Kojitani N, Yoshioka Y, Sakurai N, Sugiyama Y, Kunishita Y, Kishimoto D, Higashitani K, Sato Y, Komiya T, Nagai H, Hamada N, Maeda A, Tsuchida N, Hirahara L, Soejima Y, Takase-Minegishi K, Kirino Y, Sada K, Miyawaki Y, Ichinose K, Ohno S, Kajiyama H, Sato S, Shimojima Y, Fujiwara M, Nakajima H. Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-of-hydroxychloroquine-with-the-incidence-of-infectious-disease-in-systemic-lupus-erythematosus-data-from-the-luna-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-hydroxychloroquine-with-the-incidence-of-infectious-disease-in-systemic-lupus-erythematosus-data-from-the-luna-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology